Full results from a phase 3 trial published in The Lancet show that an experimental once-daily pill cut the risk of pulmonary arterial hypertension getting worse by 55% compared with placebo, in patients already taking standard treatment.
The most important sentence for patients comes next. Ralinepag is not approved by the FDA, cannot be prescribed, and its maker says it plans to submit an application for approval sometime in the second half of this year.
